Millions of Americans who currently buy cheaper medications shipped from Canada could see higher prices or reduced access after a U.S. customs rule takes effect later this month. Several outlets report that the change, tied to U.S. Customs and Border Protection policy, targets how certain low-value shipments are treated at the border.
The rule focuses on the “de minimis” exemption, which previously made it easier for packages valued under $800 to clear customs. Critics in the United States say the Oct. 22 shipping change could disrupt cross-border prescriptions and increase costs for people relying on them. Coverage also notes that the change is drawing pushback from Democrats and some Republicans, with cost of living concerns playing a key role in the broader political debate ahead of midterm elections. The White House, meanwhile, continues to emphasize lower drug prices as a policy priority, even as opponents argue the customs update may have the opposite effect for patients.
